Acadia Pharmaceuticals
Develops NUPLAZID and DAYBUE for neurological and rare diseases.
Something off on this page? Send us feedback.
Breakdown13F · Form 4
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 171.24M · Float —
Float — provider float is below the insider stake.
The provider's float is smaller than the insider stake it should exclude, so it is not shown.
Institutions13F, as of Jun 30, 2026
362 holders · 173.09M shares · 48 new positions · 184 increased · 109 reduced · 43 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Baker Bros. Advisors LP | 42.91M | 25.06% | +16.2K | Aug 14, 2026 |
| BlackRock, Inc. | 22.52M | 13.15% | +964.3K | Aug 7, 2026 |
| State Street Corp | 9.08M | 5.30% | +743.4K | Aug 7, 2026 |
| Vanguard Portfolio Management LLC | 8.84M | 5.16% | +166.8K | Aug 13, 2026 |
| RTW Investments, LP | 7.14M | 4.17% | 0 | Aug 14, 2026 |
| Vanguard Capital Management LLC | 5.76M | 3.37% | +102.4K | Aug 13, 2026 |
| Dimensional Fund Advisors LP | 3.69M | 2.16% | +539.8K | Aug 11, 2026 |
| Geode Capital Management, LLC | 3.36M | 1.96% | −106.6K | Aug 12, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Felix J. Bakerincl. FBB3 LLC, Baker Bros. Advisors (GP) LLC +2 more | 25.40% | 43.29M | 13D | Feb 26, 2026 ↗ |
| BlackRock, Inc. | 11.90% | 19.88M | 13G | Feb 7, 2025 ↗ |
| Vanguard Portfolio Management | 5.15% | 8.78M | 13G | Apr 28, 2026 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Baker Bros. Advisors LP | director, 10 percent owner: | 39.38M | 23.00% | Jun 2, 2026 |
| Mark C. Schneyer | officer: EVP, CHIEF FINANCIAL OFFICER | 67.8K | 0.04% | Aug 7, 2026 |
| Daniel B. Soland | director | 44.0K | 0.03% | Jun 2, 2025 |
| Edmund Harrigan | director | 43.1K | 0.03% | Jun 1, 2026 |
| Elizabeth A. Garofalo | director | 33.5K | 0.02% | Jun 1, 2026 |
| Adora Ndu | director | 32.9K | 0.02% | Jun 1, 2026 |
| Laura Brege | director | 23.2K | 0.01% | Jun 1, 2026 |
| Elizabeth H.Z. Thompson | officer: EVP, Head of Research & Dev | 19.0K | 0.01% | Jul 31, 2026 |
| Adams Catherine Owen | director, officer: Chief Executive Officer | 14.8K | 0.01% | Mar 26, 2026 |
| James Kihara | officer: PRINCIPAL ACCOUNTING OFFICER | 13.1K | 0.01% | Jun 29, 2026 |
2 ten-percent owners hold 5.36M shares by Form 4, outside the officers-and-directors figure above · 25 people have not refiled in the last 18 months (45.36M shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 6, 2026 | Mark C. Schneyerofficer: EVP, CHIEF FINANCIAL OFFICER | Sale · 2 lots | 14,292 | $29.22 | 67,828 |
| Aug 5, 2026 | Mark C. Schneyerofficer: EVP, CHIEF FINANCIAL OFFICER | Sale | 5,849 | $29.00 | 67,828 |
| Jul 30, 2026 | Elizabeth H.Z. Thompsonofficer: EVP, Head of Research & Dev | Sale · 2 lots | 16,558 | $26.13 | 18,994 |
| Jun 26, 2026 | James Kiharaofficer: PRINCIPAL ACCOUNTING OFFICER | Sale | 11,421 | $26.08 | 13,088 |
| May 26, 2026 | James Kiharaofficer: PRINCIPAL ACCOUNTING OFFICER | Sale | 5,401 | $21.18 | 24,509 |
| May 4, 2026 | Mark C. Schneyerofficer: EVP, CHIEF FINANCIAL OFFICER | Sale | 3,506 | $21.79 | 66,145 |
| May 4, 2026 | James Kiharaofficer: PRINCIPAL ACCOUNTING OFFICER | Sale | 1,332 | $21.79 | 29,129 |
| Apr 7, 2026 | James Kiharaofficer: PRINCIPAL ACCOUNTING OFFICER | Sale | 1,030 | $22.20 | 27,865 |
| Apr 7, 2026 | Mark C. Schneyerofficer: EVP, CHIEF FINANCIAL OFFICER | Sale | 2,709 | $22.20 | 62,836 |
| Mar 25, 2026 | Mark C. Schneyerofficer: EVP, CHIEF FINANCIAL OFFICER | Sale | 4,177 | $21.47 | 57,299 |
CongressHouse and Senate disclosures
Not reported.